Status:
COMPLETED
Treatment of Early Aggressive Rheumatoid Arthritis (TEAR)
Lead Sponsor:
University of Alabama at Birmingham
Collaborating Sponsors:
Amgen
Barr Laboratories
Conditions:
Rheumatoid Arthritis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study is to 1)to determine if it is better to treat all early RA patients with methotrexate in combination with hydroxychloroquine plus sulfasalazine or in combination with etanerc...
Detailed Description
The ultimate goal of RA is to eliminate symptoms, restoring the patient to normal physical, social, emotional, and vocational function, and preserving the structure and integrity of joints. While dise...
Eligibility Criteria
Inclusion
- Have a diagnosis of RA for less than or equal to 3 years
- Be 18 years of age or older at the time of diagnosis
Exclusion
- Pregnant or lactating women
- History of chronic infection, such as hepatitis, pneumonia, or chronic skin infections
- Active TB or evidence of latent TB
Key Trial Info
Start Date :
May 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2009
Estimated Enrollment :
755 Patients enrolled
Trial Details
Trial ID
NCT00259610
Start Date
May 1 2004
End Date
June 1 2009
Last Update
July 17 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Alabama at Birmingham
Birmingham, Alabama, United States, 35294